Toggle Health Problems and D

Resveratrol for Alzheimer's disease – Sept 2017

Ann N Y Acad Sci. 2017 Sep;1403(1):142-149. doi: 10.1111/nyas.13431
Sawda C1, Moussa C1,2, Turner RS1,2.


The word VITAMIN does not occur once in the PDF
Resveratrol improves health (Vitamin D receptor, etc.)

Alzheimers-Cognition - Overview starts with

 Download the PDF from VitaminDWiki
Caption Alzheimer’s disease (AD) as a metabolic disorder. Risk factors for mild cognitive impairment (MCI) and AD with aging include caloric excess and sedentary lifestyle, leading to insulin and glucose dysregulation. In contrast, exercise and caloric restriction (or intermittent fasting) may delay or prevent cognitive decline with aging. Prodromal AD refers to individuals who are cognitively intact but have a positive AD biomarker. Resveratrol may mimic effects of caloric restriction by activation of sirtuins—deacetylases that link energy balance (via NAD+/NADH regulation) to altered gene transcription (via epigenetics). Thus, although classically considered as non-modifiable risk factors for AD, genetics and aging may be modifiable.


The amyloid hypothesis suggests that the progressive accumulation and deposition of central nervous system (CNS) amyloid with aging is the proximate cause of Alzheimer's disease (AD). Thus, targeting molecular mechanisms of aging may be a viable treatment approach. Caloric restriction prevents diseases of aging, including AD, in animal models, perhaps by activation of sirtuins. The sirtuins (e.g., mammalian SIRT1) are deacetylases that link energy balance (NAD+ /NADH) to regulation of gene transcription. Resveratrol is a potent activator of SIRT1, and thus may mimic caloric restriction to prevent diseases of aging. We conducted a randomized, double-blind, placebo-controlled, phase II trial of resveratrol for individuals with mild-to-moderate AD. Resveratrol

  • (1) is detectable in cerebrospinal fluid (at low nanomolar levels),
  • (2) is safe and well tolerated,
  • (3) alters AD biomarker trajectories,
  • (4) preserves blood-brain barrier integrity, and
  • (5) modulates the CNS immune response.

Further studies are needed to determine the safety and efficacy of resveratrol and the validity of this approach in the treatment and prevention of AD and other diseases of aging.

Conclusions (from PDF)

Further studies are now needed to determine whether resveratrol and similar polyphenols may be beneficial for AD or other disorders of aging. Another phase II study is warranted to examine the safety and efficacy of higher doses and improved formulations with better pharmacokinetics and bioavailability. Similarly, as with the anti-Ap antibody and BACE1 inhibitor studies, the next trial of resveratrol may enroll a different study population, such as those with prodromal AD or normal older individuals at risk (e.g., earlier along the AD spectrum). The working hypothesis is that resveratrol may delay or prevent AD onset when given to subjects with prodromal AD or cognitively normal individuals at risk. Alternatively, novel patentable molecules—sirtuin activators (STACs) and resveratrol mimetics—may be developed. Instead of approaching each disease of aging individually, with one or more drugs prescribed for each, targeting regulatory molecules of aging per se may target several diseases of aging simultaneously, thus minimizing polypharmacy and its associated risks and costs. While neurotransmitter-based therapies are the first wave of AD treatments, and amyloid agents the second wave (perhaps), the next wave may target aging mechanisms.

Created by admin. Last Modification: Saturday April 27, 2019 21:09:18 GMT-0000 by admin. (Version 8)
Resveratrol for Alzheimer's disease – Sept 2017        
984 visitors, last modified 27 Apr, 2019,
(Cached) Printer Friendly PDF this page! Follow this page for updates

Attached files

ID Name Comment Uploaded Size Downloads
11845 Alz Resveratrol Fig2.jpg admin 27 Apr, 2019 20:54 32.88 Kb 229
11844 Alz Resveratrol Fig1.jpg admin 27 Apr, 2019 20:54 23.39 Kb 176
11843 Resveratrol for Alzheimer's disease.pdf admin 27 Apr, 2019 20:53 456.06 Kb 175
See any problem with this page? Report it (FINALLY WORKS)